Navigation Links
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Date:8/27/2008

- Clinical data showing unprecedented 89% reduction in risk of GIST relapse with use of Gleevec after surgery are basis for FDA, EMEA, Swissmedic

filings - Historically, one in two patients experienced recurrence of GIST after

surgery - Regulatory submissions reflect continued commitment to bringing new

therapeutic approaches to patients with rare diseases

EAST HANOVER, N.J., Aug. 27 /PRNewswire/ -- Novartis announced today that Gleevec(R) (imatinib mesylate) tablets* has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST). FDA priority review status is granted to therapies that could potentially fill a currently unmet medical need and accelerates the standard review timing from ten to six months(1). Similar regulatory submissions have been filed in the European Union and Switzerland and will be filed in other countries shortly.

* Known as Glivec(R) (imatinib) outside the US, Canada and Israel.

The Gleevec submissions are based on data from a Phase III, double-blind, randomized, multicenter, international study of more than 700 GIST patients who had surgery to remove their tumors. The results showed a dramatic 89% reduction in risk of kit-positive GIST returning after surgery (adjuvant setting) in patients treated with Gleevec versus placebo(2).

In early 2007, the study met its primary efficacy endpoint, showing an advantage for Gleevec in recurrence-free survival. At that time, following the recommendation of the independent study data monitoring committee to stop the trial accrual early, the study investigators made public the interim results and offered Gleevec to patients receiving placebo(3).

Approximately half of all patients with newly diagnosed GIST are considered candidates for surgical re
'/>"/>

SOURCE Novartis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
2. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
3. Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores
4. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
5. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
6. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
7. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
10. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
11. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... are efficient but involve a range of resource ... seed) and pine resin and a clever recycling ... a highly interesting alternative. Their study will be ... . , ,We think our discovery can open ... the batteries of the future, says Daniel Brandell, ...
(Date:9/29/2014)... September 29, 2014 ... "Epigenetics Market by Product (Modifying Enzymes, DNA Polymerase, ... Conversion Kit, Reagents), by Research Area (Developmental ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, opportunities, current market trends, and strategies ...
(Date:9/29/2014)... (PRWEB) September 29, 2014 ACEA ... Yale University the 2014 iCELLigence Research Grant for ... ACEA’s iCELLigence instrument is an impedance based real-time ... candidate in Department of Biomedical Engineering at Yale ... Chen’s research projects in Professor Rong Fan's ...
(Date:9/29/2014)... Burnham Securities Inc. ("Burnham"), a financial ... leader in healthcare venture development and strategic transactions ... expand the range of services each company can ... Securities will be supported by a team of ... in healthcare industry to build a healthcare franchise. ...
Breaking Biology Technology:Smart, eco-friendly new battery to solve problems 2Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3
... to add new apoA1 measurement and apoB:apoA1 ratio to its, ... ... heart disease, BIRMINGHAM, Ala., Nov. 6 ... its VAP(R),Cholesterol Test in booth No. 2918 at the American Heart ...
... Inc. (Pink,Sheets: SNDY) is pleased to announce that the ... from the St. Mary,s,Hospital in Waterbury, CT. St. Mary,s ... yrs and it has chosen to continue using the,Company,s ... vital role in the history of Greater,Waterbury, providing nearly ...
... Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) announced today that it ... Global Investment Conference to be held,November 10-12, 2008 at ... of,Access is scheduled to speak on Tuesday, November 11, ... corporate overview and discuss the Company,s,product opportunities., The ...
Cached Biology Technology:Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008 2Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital 2Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference 2
(Date:9/29/2014)... at Washington State University have concluded that nondigestible ... may help prevent disorders associated with obesity. ... assess these compounds in apple cultivars grown in ... of the journal Food Chemistry ., "We ... source of these nondigestible compounds but there are ...
(Date:9/29/2014)... Behavioral Brain Research provides novel insight into ... of chronic alcohol exposure that can lead to disruptions ... research indicate that individuals with alcohol use disorders frequently ... people are actively drinking, when they are going through ... disturbances can last for months, or even years, after ...
(Date:9/29/2014)... Pangea was starting to break up and dog-sized dinosaurs were ... phytosaurs and rauisuchids were at the top of the food ... didn,t interact much as the former was king of the ... are changing, thanks largely to the contents of a single ... the German journal Naturwissenschaften , Stephanie Drumheller ...
Breaking Biology News(10 mins):An apple a day could keep obesity away 2Tooth buried in bone shows prehistoric predators tangled across land, sea 2
... of Oceanography at UC San Diego have developed a ... algae. As reported in this week,s online edition ... Sciences , Scripps graduate student Emily Trentacoste led the ... growth component in biofuel production. In the quest ...
... In what is anticipated to be a major step ... Cell Foundation (NYSCF) Research Institute is partnering with the ... NYSCF scientists will generate stem cell lines from ... researchers to better understand and potentially treat select rare ...
... Smaller bowl sizes may be the next weapon in the battle ... in the Journal of Pediatrics which found children not ... also eat 52 percent more. , "The quickest way parents ... smaller bowl," comments Brian Wansink, professor of behavioral economics and the ...
Cached Biology News:Scripps oceanography researchers engineer breakthrough for biofuel production 2NYSCF and NIH create cell models of rare and undiagnosed diseases 2NYSCF and NIH create cell models of rare and undiagnosed diseases 3
... designed to stabilize the biomolecules during ... There are neither animal proteins ... a convenient 10 times solution in ... to other traditional lyophilizing additives such ...
... benchtop incubator-shaker, has the smallest footprint of all ... 540 x 680 mm (W x D) does ... 505 x 510mm). Available in 25 mm or ... for shaking applications requiring controlled speed and temperature ...
... the smallest thermal cyclers on the market, which ... 0.5ml (20 samples) or 0.2ml microtube (25 samples) ... and cooling rate of 3.6C/sec and 2.0C/sec respectively ... Fast track programming with new quick dial facility ...
... StabilZyme HRP Conjugate Stabilizer is an ... protein and other non-toxic stabilizing chemicals in ... 6.2 6.7. This product contains ... and 20 ppm Proclin 300 (Rohm and ...
Biology Products: